NCT06962787 - A Study of BL-B01D1 + Axitinib Without or With Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions

Renal Cancer

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

axitinib

Oral administration, and twice daily with an interval of 12 hours.

DRUG

pembrolizumab

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY